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Background: 15d-PGJ2 has been known to act as an anti-in-
flammatory agent and has anti-hypertensive effects. As a re-
sult of these properties, we examined the effect of 15d-PGJ2 
on the LPS-induced IL-8/CXCL8 mRNA expression in 
VSMCs from SHR. Methods: Effect and action mechanism 
of 15d-PGJ2 on the expression of LPS-induced IL-8/CXCL8 
mRNA in VSMCs from SHR and WKY were examined by us-
ing real-time polymerase chain reaction, electrophoretic mo-
bility shift assay for NF-κB avtivity, Western blotting analy-
sis for ERK and p38 phosphorylation and flow cytometry for 
NAD(P)H oxidase activity. Results: 15d-PGJ2 decreased the 
expression of LPS-induced IL-8/CXCL8 mRNA in WKY 
VSMCs, but increased the expression of LPS-induced 
IL-8/CXCL8 mRNA in SHR VSMCs. The upregulatory effect 
of 15d-PGJ2 in SHR VSMCs was mediated through PPARγ, 
and dependent on NF-κB activation and ERK pho-
sphorylation. However, inhibition of the p38 signaling path-
way augmented the upregulatory effect of 15d-PGJ2 on 
LPS-induced IL-8/CXCL8 mRNA. A NAD(P)H oxidase in-
hibitor inhibited the upregulatory effect of 15d-PGJ2 on LPS- 
induced IL-8/CXCL8 mRNA expression in SHR VSMCs, and 
an increase in NAD(P)H oxidase activity was detected in 
SHR VSMCs treated with 15d-PGJ2/LPS. Conclusion: Our 
results indicate that the upregulatory effect of 15d-PGJ2 on 
LPS-induced IL-8/CXCL8 expression in SHR VSMCs is 
mediated through the PPARγ  and ERK pathway, and may be 
related to NAD(P)H oxidase activity. However, p38 in-
activation may also play an important role in 15d-PGJ2/ 
LPS-induced IL-8/CXCL8 expression in SHR VSMCs.
[Immune Network 2009;9(2):64-73]
INTRODUCTION
Infiltration of inflammatory cells and oxidative stresses in vas-
cular  walls  have  been  shown  to  contribute  to  the  patho-
genesis  of  hypertension  (1-4),  and  monocytes/macrophages 
infiltration  and  the  proliferation  of  VSMCs  and  endothelial 
c e l l s  i n  a r t e r i a l  w a l l s  a r e  m e d i a t e d  b y  c h e m o k i n e s  ( 5 , 6 ) .  
Chemokine IL-8/CXCL8 is known to play an important role 
in the migration of monocytes into the subendothelial space 
in  the  early  phase  of  atherosclerosis,  and  along  with 
MCP-1/CCL2, plays an important role in the pathogenesis of 
atherosclerosis (7). In addition, elevated levels of IL-8/CXCL8 
are associated with an increased risk of future coronary artery 
disease (8). IL-8/CXCL8 may directly enhance membrane per-
meability  to  Ca
2＋;  thus,  inducing  vasoconstriction  in  the 
smooth  muscle  cells  (9).  Moreover,  we  have  previously 
shown that expression of IL-8/CXCL8 in SHR VSMCs is stron-
ger  than  in  WKY  VSMCs  (10).  Therefore,  it  has  been  sug-
gested that IL-8/CXCL8 is also involved in the pathogenesis 
and maintenance of hypertensive vascular wall formation in 
hypertension.
    PPAR ligands have been known to reduce systemic blood 
pressure (11-13), increase production of a potent endogenous 
vasodilator, NO and act as an anti-inflammatory agent (14,15). 
15d-PGJ2,  a  metabolite  of  prostaglandin  PGD2,  is  a  natural 
and high affinity ligand for PPARγ (16).  It is known to pro-
duce anti-hypertensive effects, such as inhibiting cell migra-
tion and proliferation in rat and human VSMCs, and stimulat-
ing HO-1 expression in rat VSMCs (17-19). 15d-PGJ2 also in-
hibits  the  production  of  inflammatory  mediators  (TNF-α, 15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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IL-6,  IL-1β,  IL-2,  IP-10,  MCP-1,  gelatinase  B,  and  cyclo-
oxygenase-2) and reduces the expression of iNOS (15,20-22). 
As a result of these effects, 15d-PGJ 2 has been suggested to 
be a  potential  therapeutic compound  for use as an  anti-in-
flammatory  agent.  However,  there  are  also  evidences  that 
15d-PGJ2 can promote inflammation (23-26). Thus, the role 
and effects of 15d-PGJ2 on inflammation is complex and re-
mains controversial. Moreover, the precise role of 15d-PGJ2 
in  hypertensive  VSMCs  is  not  yet  fully  understood. 
  Therefore, the aim of this study is to investigate the action 
mechanism  of  15d-PGJ2  on  LPS-induced  IL-8/CXCL8  expre-
ssion  in  VSMCs  from  SHR. 
MATERIALS AND METHODS
Reagents
Trizol reagent, lipofectamine 2000 and rat p38 siRNA oligom-
ers were purchased from Invitrogen (Carlsbad, CA). Dulbec-
co's  phosphate-buffered  saline  (PBS),  Dulbecco's  modified 
Eagle's  medium  (DMEM),  penicillin-streptomycin  and  fetal 
bovine  serum  (FBS)  were  purchased  from  Gibco/BRL  (Life 
Technologies,  Gaithersburg,  MD).  15d-PGJ2  and  GW9662 
were  purchased  from  Biomol  (Plymouth  Meeting,  PA). 
Escherichia coli LPS (O111:B4), diphenyleneiodonium chlor-
ide (DPI), dithiothreitol (DTT), phenylmethylsulfonyl fluoride 
(PMSF), pepstatin, leupeptin, autipain, and aprotinin were ob-
tained from Sigma Chemical Co. (St. Louis, MO). MAPK in-
hibitors, 2'-amino-3'methoxyflavone (PD98059), 4-(4-fluorophenyl)- 
2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole (PD169316), and 
NF-κB  inhibitor,  (E)3-[(4-Methylphenyl)sulfonyl]-2-propene-
nitrile (Bay 11-7082) were purchased from Calbiochem (San 
Diego, CA). Dichlorofluorescein diacetate (DCF-DA) was ob-
tained  from  Molecular  probes  (Eugene,  OR).  Nitrocellulose 
transfer membranes were obtained from Schleicher & Schuell 
Bioscience  (Dassel,  Germany).  [α-
32P ] d C T P  w a s  p u r c h a s e d  
from Dupont-New England Nuclear (Boston, MA). Oligonu-
cleotide  primers  for  polymerase  chain  reaction  (PCR)  of 
IL-8/CXCL8, PPAR and β-actin were synthesized by Bionics 
(Seoul,  Korea). The LightCycler  FastStart  DNA SYBR Green 
I  Mix  was  obtained  from  Roche  (Mannheim,  Germany). 
Anti-NF-κB, Phospho-ERK and phospho-p38 antibodies were 
obtained from Cell Signaling Technology (Danvers, MA). The 
γ-tubulin antibody was obtained from Sigma Chemical Co. 
(St Louis, MO). All other reagents were from pure-grade com-
mercial  preparations.
Experimental animal
Specific pathogen-free male inbred WKY and SHR, 20 to 30 
w e e k s  o f  a g e ,  w e r e  p u r c h a s e d  f r o m  J a p a n  S L C  I n c .  
(Shizuoka,  Japan).  All  experimental  animals  received  auto-
claved  food  and  bedding  to  minimize  exposure  to  viral  or 
microbial pathogens. The rats were cared for in accordance 
with the Guide for the Care and Use of Experimental Animals 
of  Yeungnam  Medical  Center.
VSMCs preparation
VSMCs  were  obtained  from  the  thoracic  aortas  of  20-  to 
30-week-old  male  WKY  and  SHR  as  described  previously 
(25).  VSMCs  were  cultured  in  Dulbecco's  modified  Eagle's 
medium (DMEM) that was supplemented with 10% FBS and 
1% penicillin-streptomycin. Cells were detached using 0.25% 
trypsin/EDTA and seeded into 75-cm
2 tissue culture flasks at 
a density of 10
5 cells per ml. All experiments were conducted 
at  cell  passage  3  to  7.  Prior  to  stimulation,  95%  confluent 
VSMCs were serum-starved overnight by incubating in DMEM 
with 0.1% FBS. Cell cultures were incubated in a humidified 
incubator  at  37
oC  and  5%  CO2  in  the  presence  or  absence 
of  stimuli  for  the  indicated  times.
Preparation of total RNA and real-time polymerase 
chain reaction (real-time PCR)
Total RNA was extracted using a Trizol reagent in accordance 
with  the  manufacturer's  instructions.  The  quantity  of  total 
RNA obtained was determined by measuring optical density 
(OD) at 260 and 280 nm. Real-time PCR for the amplification 
of IL-8/CXCL8 and PPARγ in VSMCs was performed using 
a LightCycler (Roche). RNA was reverse transcribed to cDNA 
from 1 μg of total RNA, and then subjected to real-time PCR. 
PCR was performed in triplicate. The total PCR volume was 
20  μl  and  contained  the  LightCycler  FastStart  DNA  SYBR 
Green I mix (Roche), appropriate primer and 2 μl of cDNA. 
Prior to PCR amplification, the mixture was incubated at 95
oC 
for 10 min, and the amplification step consisted of 45 cycles 
of  denaturation  (10  s  at  95
oC),  annealing  (5  s  at  the  pri-
mer-appropriate temperature), and extension (10 s at 72
oC) 
with fluorescence detection at 72
oC after each cycle. After the 
final cycle, melting point analyses of all samples were per-
formed over the range of 65 to 95
oC  with  continuous fluo-
rescence  detection.  β-actin expression levels  were  used  for 
sample normalization. Results for each gene were expressed 
as the relative expression level compared with β-actin. The 
primers used for PCR were as follows: for IL-8/CXCL8 (365 15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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bp) sense, 5'-gaagatagattgcaccga-3'; antisense, 5'-catagcctctca-
cacatttc-3',  for  PPARγ (359  bp):  sense,  5'-tgaggagaagtca-
cactctg-3'; antisense, 5'-tgggtcagctcttgtgaatg-3' and for β-actin 
(101 bp): sense, 5'-tactgccctggctcctagca-3'; antisense, 5'-tgga-
cagtgaggccaggatag-3'. The level of IL-8/CXCL8 mRNA was de-
termined  by  comparing  experimental  levels  to  the  standard 
curves and was expressed as the fold of relative expression.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described previously (25). 
Cells were washed three times with cold PBS, then scraped 
and  harvested  by  centrifugation.  Cell  pellets  were  re-
suspended  and  incubated  on  ice  for  15  min  in  400  μl  of 
hypotonic buffer A (10 mmol/l  HEPES, 10 mmol/l KCl, 1.5 
mmol/l MgCl2, 0.5 mmol/l DTT, 0.1 mmol/l PMSF, 10 μg/ml 
pepstatin, 10 μg/ml leupeptin, 10 μg/ml autipain, and 10 
μg/ml aprotinin).  Nonidet  P-40  was  then  added  to  a  final 
concentration of 2.5%, and the cells were vortexed for 10 s. 
Nuclei were separated from the cytosol by centrifugation at 
12,000 g for 15 s. Pellets were resuspended in 40 μl of hypo-
t o n i c  b u f f e r  C  ( 2 0  m m o l / l  H E P E S ,  2 5 %  g l y c e r o l ,  0 . 4  m o l / l  
NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 0.5 mmol/l DTT, 0.1 
mmol/l PMSF, 10 μg/ml pepstatin, 10 μg/ml leupeptin, 10 
μg/ml autipain, and 10 μg/ml aprotinin). Samples were so-
nicated at level 3-4 for 2-3 s, followed by centrifugation for 
1 0  m i n  a t  4
oC .  T h e  n u c l e a r  p r o t e i n  c o n c e n t r a t i o n  w a s  d e -
termined using the Bradford assay (Bio-Rad, Richmond, CA). 
A consensus sequence for the NF-κB DNA binding site (5'- 
AGTTGAGGGGACTTTAGGC-3')  (sc-2505;  Santa  Cruz  Bio-
technology,  Santa  Cruz,  CA)  was  labeled  with  [α-
32P]dCTP 
using a random-primed DNA labeling kit (Roche). The mutant 
NF-κB binding sequence was identical to sc-2505 except for 
a "G" → "C" substitution in the NF-κB DNA binding motif 
(sc-2511; Santa Cruz Biotechnology). DNA The labeled DNA 
was purified over an S-200 HR column (Pharmacia, Piscataway, 
NJ) to remove unbound nucleotides. Nuclear protein extracts 
were incubated at room temperature for 20 min with approx-
imately 50,000 cpm of labeled oligonucleotides that were sus-
pended in the binding buffer [200 mmol/l HEPES, 500 mmol/l 
KCl,  10  mmol/l  EDTA,  50%  glycerol,  10  mmol/l  DTT,  1 
mg/ml  BSA,  1  μg/μl  poly  (dI-dC)].  Following  this  in-
cubation, samples were resolved on 4% polyacrylamide gels 
at  140  V  and  exposed  to  film.
Western blotting
Total lysates were prepared in a PRO-PREP buffer (iNtRON, 
Seoul, Korea). Protein concentrations were determined by a 
Bradford  assay  using  bovine  serum  albumin  as  a  standard. 
Thirty-micrograms of the protein samples were separated on 
10% SDS-polyacrylamide gels, and then transferred to nitro-
cellulose  membranes.  The  membranes  were  soaked  in  5% 
nonfat dried milk in TBST (10 mmol/l Tris-HCl pH 7.5, 150 
m m o l / l  N a C l  a n d  0 . 0 5 %  T w e e n - 2 0 )  f o r  1  h  a n d  t h e n  i n -
cubated for 16∼18 h with primary antibodies against phos-
pho-ERK,  phospho-p38  and  γ-tubulin  at  4
oC.  Membranes 
were washed three times with TBST for 10 min and then in-
cubated  with  horseradish  peroxidase-conjugated  secondary 
antibody for 1 h at 4
oC. After incubation with the secondary 
antibody, the membranes were rinsed three times with TBST 
for 10 min and antigen-antibody complex was detected using 
an enhanced chemiluminescence detection system (LAS-3000, 
Fujifilm,  Tokyo,  Japan).
Small interfering RNA  
To confirm whether the p38 pathway contributes to the in-
hibitory  effect  of  15d-PGJ2  on  LPS-induced  IL-8/CXCL8  ex-
pression, p38 expression was silenced using small interfering 
RNA  (siRNA).  VSMCs  were  plated  on  24-well  plates  and 
grown to 90% confluence. VSMCs were then transfected with 
p38 siRNA oligomers (20 nmol/l) using lipofectamine 2000 in 
accordance  with  the  manufacturer's  instructions.  After  24  h 
of incubation, VSMCs were placed in growth medium for 24 
h  before  the  experiments.  Cells  were  then  cultured  in  the 
presence or absence of stimuli for 4 h. Sense and antisense 
oligonucleotides  corresponding  to  the  rat  p38  siRNA  se-
quence: sense, 5'-uacauuugcgaaguucaucuucggc-3'; antisense, 
5'-gccgaagaugaacuucgcaaaugua-3'  was  purchased  from  Invi-
trogen  (Carlsbad,  CA). 
Flow cytometry for ROS generation   
ROS production was measured using flow cytometric analysis 
of DCF-DA-stained cells. In brief, VSMCs were grown to 70% 
confluence in serum-enriched DMEM at 37
oC in 5% CO2.  The 
medium was then replaced with serum-free DMEM and the 
cells were cultured in the presence or absence of stimuli for 
the  indicated  times.  Cells  were  incubated  in  the  dark  with 
DCF-DA  (50  μm o l / l )  f o r  1  h  a t  3 7
oC,  scraped,  and  re-
suspended in  PBS. Fluorescence  was  monitored using  flow 
cytometry  (FACScan,  Becton  Dickison). 
Statistical analysis
Results  are  expressed  as  means±SD  from  at  least  three  or 15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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Figure 1. Effect of 15d-PGJ2 on the expression of LPS-induced IL-8/CXCL8 mRNA in VSMCs from SHR and WKY, and the time course of 
15d-PGJ2/LPS-induced IL-8/CXCL8 mRNA expression in SHR VSMCs. (A) VSMCs were untreated (NT) or treated with LPS (1 μg/ml) or/and 15d-
PGJ2 (10 μM) for 4 h, and the total RNA was analyzed by real-time PCR. Bars represent means±SD from three independent experiments. *p＜0.05
vs. VSMCs treated with LPS alone. (B) SHR VSMCs were untreated (NT) or treated with LPS (1 μg/ml) or LPS plus 15d-PGJ2 (10 μM) simul-
taneously (15d-PGJ2/LPS) for the indicated times and the total RNA was analyzed by real-time PCR. Bars represent means±SD from three 
independent experiments.
four independent experiments. For comparison between mul-
tiple  groups,  statistical  significance  was  determined  by  the 
Mann-Whitney  test  using  the  SPSS  version  12.0.
RESULTS
Effect of 15d-PGJ2 on the LPS-induced IL-8/CXCL8 
expression in SHR VSMCs  
We  examined  the  differential  effect  of  LPS  on  IL-8/CXCL8 
m R N A  e x p r e s s i o n  i n  S H R  V S M C s  i n  c o m p a r i s o n  t o  W K Y  
VSMCs. From this experiment, we found that the expression 
of LPS-induced IL-8/CXCL8 mRNA was greater in SHR VSMCs 
t h a n  W K Y .  R e a l - t i m e  P C R  w a s  p e r f o r m e d  o n  V S M C s  a f t e r  
they were untreated (NT) or treated with LPS (1 μg/ml), 15d- 
PGJ2 (10 μM) or LPS plus 15d-PGJ2 simultaneously (15d-PGJ2/ 
LPS) for 4 h. 15d-PGJ2 treatment had different effects on SHR 
VSMCs relative to WKY VSMCs, where 15d-PGJ2 had upregu-
latory effect on LPS-induced IL-8/CXCL8 mRNA expression in 
SHR VSMCs and suppressive effect on LPS-induced IL-8/CXCL8 
m R N A  e x p r e s s i o n  i n  W K Y  V S M C s .  1 5 d - P G J 2 a l o n e  d i d  n o t  
i n d u c e  I L - 8 / C X C L 8  m R N A  e x p r e s s i o n  i n  S H R  V S M C s  s i g -
nificantly (Fig. 1A). The time course of 15d-PGJ2/LPS-induced 
IL-8/CXCL8 mRNA expression was determined in SHR VSMCs 
over a 0 to 8 h time period. In this experiment, we found 
that the expression of IL-8/CXCL8 mRNA induced by 15d-PGJ2/ 
LPS was almost the same as that for cells treated with LPS 
alone until 2 h after treatment. However, the expression lev-
els of IL-8/CXCL8 mRNA induced by 15d-PGJ2/LPS were sig-
nificantly greater than those in the cells treated with LPS alone 
f r o m  t h e  4  h  p e r i o d  ( F i g .  1 B ) .  
Action mechanisms of 15d-PGJ2 on LPS-induced 
IL-8/CXCL8 expression in SHR VSMCs 
It is widely accepted that 15d-PGJ2 exerts its effects on pro-in-
flammatory  genes  in  cells  through  PPARγ dependent  or 
PPARγ independent mechanisms (27-29). Before evaluating 
whether  the  mechanism  of  the  upregulatory  action  of 
15d-PGJ2  in  SHR  VSMCs  was  PPARγ-dependent,  we  de-
termined  the  expression  pattern  of  PPARγ mRNA  in  SHR 
VSMCs treated with 15d-PGJ2/LPS. There was no meaningful 
difference between the level of PPARγ expression induced 
by  15d-PGJ2/LPS  and  that  induced  by  15d-PGJ2  alone  (Fig. 
2A). To evaluate whether the upregulatory effect of 15d-PGJ2 
in SHR VSMCs is mediated by PPARγ, the effect of GW9662, 
a  PPARγ antagonist,  was  tested  in  SHR  VSMCs.  GW9662 
blocked  LPS-induced  IL-8/CXCL8  mRNA  expression  at  the 
dose of 10 μM. And, although 10 μM of GW9662 did not 
block  the  upregulatory  effect  of  15d-PGJ2  on  LPS-induced 
IL-8/CXCL8 mRNA expression, the high doses (40 and 100 μM) 
of GW9662 inhibited the upregulatory effect of 15d-PGJ2 on 
LPS-induced  IL-8/CXCL8  mRNA  expression  (Fig.  2B). 
    To further understand the nature of the upregulatory effect 
of 15d-PGJ2 on LPS-induced IL-8/CXCL8 expressions in SHR 
V S M C s ,  t h e  r o l e  o f  N F - κB  activation  was  investigated. 
Bay11-7082 is known to selectively block the phosphorylation 
of IκB-α; thus, preventing the activation and nuclear trans-15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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Figure 3. Upregulatory effect of 15d-PGJ2 on LPS-induced IL-8/CXCL8
mRNA expression is dependent on NF-κB activation in SHR VSMCs.
(A) VSMCs were untreated or treated with LPS (1 μg/ml) and/or 
15d-PGJ2 (10 μM) in the absence or presence of Bay11-7082 (10 μ
M) for 4 h. Bars represent means±SD from three independent 
real-time PCR experiments. a: p＜0.05 vs. VSMCs treated with LPS 
alone. b: p＜0.05 vs. VSMCs treated with 15d-PGJ2/LPS. (B) Specific 
binding activity of NF-κB from nuclear extracts was assessed by 
EMSA. Aliquots of the nuclear extract were incubated with a 100-fold
excess of the mutant probe (m) or with 2 μg of the anti NF-κB 
antibody before EMSA. Data shown are representative of four 
independent experiments.
Figure 2. Upregulatory effect of 15d-PGJ2 on LPS-induced IL-8/CXCL8 
mRNA expression is dependent on the PPARγ pathway in SHR 
VSMCs. (A) VSMCs were untreated (NT) or treated with LPS (1 μg/ml)
and/or 15d-PGJ2 (10 μM) for 4 h, and the total RNA was analyzed 
by real-time PCR. Bars represent means±SD from three independent 
experiments. (B) VSMCs were untreated or treated with LPS (1 μg/ml) 
and/or 15d-PGJ2 (10 μM) in the absence or presence of GW9662 (10,
40, and 100 μM) for 4 h. Bars represent means±SD from three 
independent experiments. *p＜0.05 vs. VSMCs treated with 15d-PGJ2/
LPS.
location of NF-κB. Real-time PCR and EMSA were performed 
on VSMCs after they were untreated or treated with LPS (1 
μg/ml) and/or 15d-PGJ2 (10 μM)  in the absence or pres-
ence of Bay11-7082 (10 μM) for 4 h. Bay11-7082 remarkably 
blocked the upregulatory effect of 15d-PGJ2 on LPS-induced 
IL-8/CXCL8 mRNA expression. And it also remarkably blocked 
LPS-induced  IL-8/CXCL8  expression  (Fig.  3A).  However,  in 
spite  of  negative  NF-κB  activity  in  cells  treated  15d-PGJ2 
alone, NF-κB activity in SHR VSMCs treated with15d-PGJ2/ 
LPS  was  remarkably  increased  compared  to  the  activity  in 
c e l l s  t r e a t e d  w i t h  L P S  a l o n e  ( F i g .  3 B ) .  
    Next  we  investigated  whether  the  MAPK  signaling  path-
ways are involved in the upregulatory effect of 15d-PGJ2 in 
SHR VSMCs. After VSMCs were untreated (NT) or pretreated 
with PD98059 (ERK inhibitor, 10 μM, 4A), or PD169316 (p38 
inhibitor,  10  μM ,  5 A )  f o r  3 0  m i n ,  c e l ls  were  untreated  or 
treated  with  LPS  (1  μg/ml)  and/or  15d-PGJ2  (10  μM)  for 
4 h. Real-time PCR was then performed on these treated cells. 
In  addition,  these  results  were  further  confirmed  by  inves-
tigating  the phosphorylation of  MAP kinases  in  VSMCs  that 
had been treated with 15d-PGJ2/LPS. The expression of 15d- 
PGJ2/LPS-induced  IL-8/CXCL8  mRNA  was  decreased  by  the 
ERK inhibitor PD98059. And the expression of LPS alone-in-
duced  IL-8/CXCL8  mRNA  was  also  decreased  by  PD98059 
(Fig.  4A).  However,  although  ERK phosphorylation in  cells 
treated  15d-PGJ2 a l o n e  w a s  n o t  d e t e c t e d ,  a  r e m a r k a b l e  i n -
crease  in  ERK  phosphorylation  in  VSMCs  that  were  treated 
with 15d-PGJ2/LPS relative to VSMCs that were treated with 
LPS alone was also detected (Fig. 4B). PD169316 increased 
the IL-8/CXCL8 mRNA expression in VSMCs stimulated with 
15d-PGJ2/LPS,  rather  than  inhibiting  IL-8/CXCL8  expression 
(Fig.  5A).  Moreover,  15d-PGJ2  decreased  LPS-induced  p38 
phosphorylation  (Fig.  5B).  More  specifically,  blocking  p38 
phosphorylation caused an increase in 15d-PGJ2/LPS-induced 
IL-8/CXCL8 expression. To confirm this result, real-time PCR 
using  p38-directed  small  interfering  RNA  (siRNA)  was 
performed. In this experiment we found that while LPS in-
hibited  the  expression  of  IL-8/CXCL8  mRNA,  15d-PGJ2 i n -
duced  IL-8/CXCL8  expression  and  15d-PGJ2/LPS  increased 
IL-8/CXCL8 mRNA expression in p38 siRNA transfected SHR 
VSMCs  (Fig.  5C). 15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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Figure 4. Upregulatory effect of 15d-PGJ2 on LPS-induced IL-8/CXCL8
expression is mediated through the ERK pathway in SHR VSMCs. (A)
VSMCs were untreated (NT) or pretreated with PD98059 (ERK 
inhibitor, 10 μM) for 30 min, and then untreated or treated with LPS
(1  μg/ml) and/or 15d-PGJ2 (10 μM) for 4 h. Real-time PCR was 
performed after total mRNAs were isolated. Bars represent means±SD
from three independent experiments. a: p＜0.05 vs. VSMCs treated 
with LPS alone. b: p＜0.05 vs. VSMCs treated with 15d-PGJ2/LPS. (B)
Cell lysates were separated on 10% SDS-polyacrylamide gels and then
immunoblotted with the phospho-ERK antibody. The data shown are
representative of three independent experiments.
Figure 5. Blocking of p38 phosphorylation increased the expression of 
15d-PGJ2/LPS-induced IL-8/CXCL8 mRNA expression in SHR VSMCs. 
(A) VSMCs were untreated (NT) or pretreated with PD169316 (p38 
inhibitor, 10 μM) for 30 min, and then untreated or treated with LPS
(1 μg/ml) and/or 15d-PGJ2  (10 μM) for 4 h. Real-time PCR was per-
formed after total mRNAs were isolated. Bars represent means±SD
from three independent experiments. *p＜0.05 vs. VSMCs treated with 
15d-PGJ2/LPS. (B) Cell lysates were separated on 10% SDS-poly-
acrylamide gels and then immunoblotted with the phospho-p38 anti-
body. Data shown are representative of four independent experiments.
(C) VSMCs were plated on 24-well plates, grown to 90% confluence 
and then transfected with p38 siRNA oligomers (20 nmol/l). VSMCs 
were then untreated or treated with LPS (1 μg/ml) and/or 15d-PGJ2
(10 μM) for 4 h. Bars represent means±SEM from three independent
experiments.
Effect of NAD(P)H oxidase activity on 15d-PGJ2/LPS- 
induced IL-8/CXCL8 expression in SHR VSMCs  
VSMCs generate reactive oxygen species (ROS), which play 
an  important  role  in  the  pathogenesis  of  hypertensive  vas-
cular  injury.  A  major  source  of  ROS  is  NAD(P)H  oxidase. 
Therefore, we investigated whether NAD(P)H oxidase activity 
is  re lat e d t o  th e  up re g ul at or y e ff ec t  of  15 d -P G J 2  on  LPS-in-
d u c e d  I L - 8 / C X C L 8  e x p r e s s i o n s  i n  S H R  V S M C s .  
    Real-time  PCR  was  performed  on  VSMCs  SHR  after  they 
were untreated or treated with LPS (1 μg/ml) and/or 15d- 
PGJ2 (10 μM) in the absence or presence of flavin containing 
oxidase inhibitor, DPI (10 μM) for 4 h. DPI remarkably de-
creased the expression of 15d-PGJ2/LPS-induced IL-8/CXCL8 
mRNA; thus, blocking the upregulatory effects of 15d-PGJ2 on 
LPS-induced  IL-8/CXCL8  expression  (Fig.  6A).  To  support 
these results, the ability of 15d-PGJ2/LPS to induce NAD(P)H 
oxidase  activity  was  examined  in  SHR  VSMCs.  ROS  gen-
eration in SHR VSMCs was measured by flow cytometric anal-
ysis of DCF-DA-stained VSMCs. DCF-DA fluorescence can be 
a l s o  u s e d  a s  a  m e a s u r e m e n t  o f  N A D ( P ) H  o x i d a s e  a c t i v i t y .  
From this analysis, SHR VSMCs treated with 15d-PGJ2/LPS was 
shown to increase DCF-DA fluorescence slightly compared to 
t h o s e  t r e a t e d  w i t h  L P S  a l o n e  ( F i g .  6 B ) .
DISCUSSION
In relation to IL-8/CXCL8 expression, 15d-PGJ2 was shown to 
have  pro-inflammatory  effects  in  SHR  VSMCs  and  anti-in-
flammatory effects in WKY VSMCs. Wakino et al. (30) also 
observed similar differential effects of PPARγ ligands on vas-
cular  tissues  from  SHR  and  WKY.  They  demonstrated  that 
pioglitazone reduces the stimulated Rho-kinase activity in the 
vascular tissue from SHR, but not WKY. Troglitazone mark-15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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Figure 6. Activity of NAD(P)H oxidase mediates the upregulatory 
effect of 15d-PGJ2 on the expression of LPS-induced IL-8/CXCL8 mRNA
in SHR VSMCs. (A) VSMCs were untreated or treated with LPS (1 μg/
ml) and/or 15d-PGJ2 (10 μM) in the absence or presence of DPI (10
μM) for 4 h. Bars represent means±SD from three independent 
experiments. *p＜0.05 vs. VSMCs treated with 15d-PGJ2/LPS. (B) 
VSMCs were untreated or treated with LPS (1 μg/ml) and/or 15d-PGJ2
(10 μM) for 4 h, stained with DCF-DA (50 μM) for ROS detection,
and subjected to flow cytometry. Bars represent means±SD from four
independent experiments. *p＜0.05 vs. VSMCs treated with LPS 
alone.
edly decreased the expression of TGFβ-1, PDGF, or bFGF 
mRNAs in SHR VSMCs, but not in WKY VSMCs (12). Therefore, 
these  different  effects  of  PPAR  ligands  on  SHR  and  WKY 
VSMCs indicate that diverse, complex pathways mediate the 
action  of  PPARg  ligands  on  hypertension. 
    The  upregulatory  effect  of  15d-PGJ2  on  LPS-induced 
IL-8/CXCL8 expression was mediated through PPARg in SHR 
VSMCs.  15d-PGJ2  and  other  cyclopentenone  prostaglandin, 
such as prostaglandin A1 (PGA 1) are known to exert effects 
on cytokine genes through PPARγ-dependent and PPARγ- 
independent mechanisms (25,26,28,29,31,32). In our previous 
studies (25,26), the upregulatory effect of 15d-PGJ2 on LPS-in-
duced  MIP-2/CXCL2  and  KC/CXCL1  gene  expression  was 
found to not mediated by the PPARγ pathway, but the effect 
of PGA1 on LPS-induced IL-10 expression was dependent on 
PPARγ in mouse peritoneal macrophages. In a separate VSMCs 
study, 15d-PGJ2-induced HO-1 expression was shown to be 
independent  of  PPARγ (19).
    In the EMSA, an increase in NF-κB activity in SHR VSMCs 
treated with 15d-PGJ2/LPS relative to VSMCs treated with LPS 
alone was detected, and the expression of 15d-PGJ2/LPS-in-
duced IL-8/CXCL8 mRNA was decreased by the presence of 
Bay11-7082. These results indicate that the upregulatory effect 
of  15d-PGJ2 i n  S H R  V S M C s  i s  d e p e n d e n t  o n  N F - κB  acti-
vation. It is widely accepted that 15d-PGJ2 exerts its effects 
on inflammatory mediated-genes in cells by either inhibiting 
or  activating  NF-κB  signaling  (24,26,33-35).  The  anti-in-
flammatory activity of 15d-PGJ2 has been shown to be medi-
ated mainly through the inhibition of NF-κB activation (33, 
34), but 15d-PGJ2 has also been shown to upregulate IL-8/ 
CXCL8 and MIP-2/CXCL2 expression through NF-κB activa-
tion  (24,26).
    Among the MAPK signaling pathways, the ERK pathway is 
known to be associated with the stimulatory activity of 15d- 
PGJ2 on the expression of some cytokine genes (23,24,36). 
15d-PGJ2 induces the rapid activation of the ERK pathway in 
VSMCs (37). We also detected an increase in ERK phosphor-
ylation  in  SHR  VSMCs  treated  with  15d-PGJ2/LPS.  Up-regu-
lation of LPS-induced IL-8/CXCL8 expression by 15d-PGJ2 was 
mediated through the ERK signaling pathway in SHR VSMCs. 
Inhibition or activation by 15d-PGJ2 on p38 MAP kinase ap-
pears  to  be  target  gene-,  cell  type-  and  stimulation  con-
dition-dependent (19,38,39). Activation of the p38 MAP kin-
ase has been shown to be involved in 15d-PGJ2-induced HO-1 
expression (19) and in IL-1β-induced IL-8/CXCL8 gene ex-
pression in human VSMCs (38). However, 15d-PGJ2 is known 
to inhibit IL-1-induced p38 MAP kinase expression in human 
astrocytes (39). In this study, blocking p38 phosphorylation 
increased  15d-PGJ2/LPS-induced  IL-8/CXCL8  expression  in 
SHR VSMCs. 15d-PGJ2 inhibited p38 phosphorylation in SHR 
VSMCs treated with LPS. Furthermore, while the expression 
o f  L P S - i n d u c e d  I L - 8 / C X C L 8  m R N A  w a s  a b o l i s h e d  i n  S H R  
VSMCs that were transfected with p38 siRNA, 15d-PGJ2/LPS- 
induced IL-8/CXCL8 expression increased. Therefore, LPS-in-
duced IL-8/CXCL8 mRNA expression appears to be related to 
p38 activation, but 15d-PGJ2 itself induces IL-8/CXCL8 mRNA 
expression without p38 activation. These combined results in-
dicate that the upregulatory effect of 15d-PGJ2 on LPS-induced 
IL-8/CXCL8 expression is related to p38 inactivation. Although 
the  upregulatory  effect  of  15d-PGJ2  on  LPS-induced  IL-8/ 
CXCL8 expression is mediated by the ERK pathway, an un-
known  mechanism  via  p38  inactivation  may  play  an  im-
portant role in 15d-PGJ2/LPS-induced IL-8/CXCL8 expression 
i n  S H R  V S M C s .15d-PGJ2 Upregulates IL-8/CXCL8 Expression in SHR VSMCs
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    NAD(P)H oxidase is a known major source of reactive oxy-
gen species (ROS). ROS are not only harmful cellular metabo-
lites but are also essential molecules in cell signaling and reg-
ulation (40). Excessive ROS generation by NAD(P)H oxidase 
i s  k n o w n  t o  p l a y  a n  i m p o r t a n t  r o l e  i n  t h e  p a t h o g e n e s i s  o f 
hypertensive vascular injury and has also been implicated in 
the  pathogenesis  of  hypertension  (1,41-44).  Cruzado  et  al. 
(41) demonstrated that ROS generation was enhanced in SHR 
VSMCs during the development of hypertension. Therefore, 
we examined the effect of NAD(P)H oxidase activity on IL-8/ 
CXCL8 expression in SHR VSMCs treated with 15d-PGJ2/LPS. 
An inhibitor of the flavin-containing oxidases, DPI, remark-
ably decreased the expression of 15d-PGJ2/LPS-induced IL-8/ 
CXCL8 mRNA. Although a significant production of ROS by 
15d-PGJ2 h a s  b e e n  r e p o r t e d  i n  S p r a g u e - D a w l e y  r a t  V S M C s  
(19) and ROS generation by LPS alone was detected in WKY 
VSMCs (data not shown), ROS generation did not increase in 
SHR  VSMCs  after  treatment  with  15d-PGJ2  or  LPS  alone. 
However, 15d-PGJ2/LPS did increase ROS generation in SHR 
VSMCs. These results suggest that the upregulatory effect of 
15d-PGJ2  on  LPS-induced  IL-8/CXCL8  expression  in  SHR 
VSMCs  may  be  related  to  NAD(P)H  oxidase  activity.
    In conclusion, this is the first study to report on the upregu-
latory effect of 15d-PGJ2 on LPS-induced IL-8/CXCL8 gene ex-
pression  in  SHR  VSMCs  and  the  inhibitory  effect  in  WKY 
VSMCs. In addition, we showed that the upregulatory effect 
of 15d-PGJ2 in SHR VSMCs is mediated through PPARγ path-
way, NF-κB and ERK activation, and p38 inactivation may 
play an important role in 15d-PGJ2/LPS-induced IL-8/CXCL8 
expression. These results provide new insight into the poten-
tial diverse effects of 15d-PGJ2 on hypertensive vascular smooth 
muscle  cells.
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